Free Guide: Everything You Need to Know About KRAS G12C Testing in NSCLC

Activating mutations in KRAS are one of the most prevalent oncogenic drivers in non-small cell lung cancer (NSCLC) and mutant KRAS remains a challenging to target. Learn how next-generation sequencing can simultaneously analyze relevant biomarkers and co-mutations essential to understanding the genomic landscape of mutant KRAS.

Please fill out the form below to download our guide with information about methods for identifying mutations in KRAS.

Are you interested in receiving a quote or demo about the Oncomine NGS Assays or the Genexus NGS System for KRAS biomarker testing in clinical research?

I agree for the Thermo Fisher Scientific group ( to contact me by e-mail and telephone to inform me of events, products, services and promotions offered in connection with the brands Thermo Scientific™ Applied Biosystems™, Invitrogen™, GibcoTM, Ion Torrent™, Unity Lab Services™, Fisher Scientific™

I can withdraw my consent and unsubscribe at any time by emailing